CNESST and Psychedelic Therapy in Quebec: Workers' Compensation Coverage Guide (2026)

For Quebec workers with an accepted CNESST claim for PTSD or chronic pain, ketamine-assisted therapy may be reimbursable on a case-by-case basis under Quebec's Loi sur les accidents du travail et les maladies professionnelles (LATMP). No formal CNESST formulary listing exists for any psychedelic or ketamine therapy — but the legal mechanism is real, the evidence base is growing, and Bill 59's PTSD presumption (in force since 2022) has widened access to compensable PTSD claims for first responders and other Quebec workers.

Key takeaways

• CNESST is Quebec's workers' compensation authority (Commission des normes, de l'équité, de la santé et de la sécurité du travail). It operates under LATMP — not RAMQ (Quebec's public health insurance).
• No CNESST formulary for ketamine, psilocybin, or MDMA exists. Coverage is case-by-case under LATMP section 189, which allows reimbursement of medications prescribed to treat a compensable injury.
• Bill 59 (in force 2022–2024) added PTSD to Quebec's occupational disease list, creating a legal presumption of work-relatedness for workers repeatedly or extremely exposed to traumatic events — including first responders.
• Ketamine is the most evidence-supported psychedelic-adjacent therapy for CNESST-eligible PTSD and chronic pain; two peer-reviewed RCTs support its efficacy for PTSD [Feder et al. 2021; Murrough et al. 2014].
• Psilocybin and MDMA require Health Canada Special Access Program (SAP) authorization before any treatment and are not listed on any Canadian workers' compensation formulary.
• CNESST and RAMQ are separate payers. Quebec's RAMQ public health insurance established a psilocybin-funding precedent in December 2022 (Farzin/Stephan) — that precedent applies to RAMQ, not CNESST.
• TAT appeal: A denied CNESST treatment request can be contested at the Tribunal administratif du travail (TAT) within 30–60 days.

What CNESST covers and how treatment reimbursement works

CNESST is Quebec's workers' compensation body, administering the Loi sur les accidents du travail et les maladies professionnelles (LATMP). Unlike WSIB Ontario — which maintains a formal drug formulary listing ketamine and esketamine on five specialty sub-formularies — CNESST does not publish a drug formulary. Instead, section 189 of LATMP gives CNESST the authority to reimburse medications and treatments prescribed by a physician specifically to treat the consequences of a compensable employment injury.

This framework is well-established for non-standard medications in Quebec. The Tribunal administratif du travail (TAT) — formerly the Commission des lésions professionnelles (CLP) — has recognized medical cannabis as reimbursable under LATMP section 189 in multiple decisions, establishing the analogical framework for other off-label therapies including ketamine. The TAT's approach in those decisions is consistent: CNESST reimburses when the prescribing physician documents (a) the medication is prescribed to treat the accepted compensable condition, (b) conventional treatments were explored without adequate results, and (c) the prescription meets applicable medical standards [TAT/CNESST jurisprudence].

For ketamine-assisted therapy, the same logic applies. A Quebec physician (CMQ-registered) prescribing ketamine for a worker's compensable PTSD or chronic pain must document the treatment's connection to the accepted claim and the prior conventional treatment failures. There is no automatic approval — CNESST evaluates each request individually.

Key contrast with other provinces:

• WSIB Ontario: formal ketamine/esketamine listings on 5 specialty formularies (Psychotraumatic, Serious Injury, Musculoskeletal, CNS/PNS, Chronic Pain Disability) with prior authorization. See workers' compensation coverage for psychedelic-assisted therapy in Canada.
• WCB Alberta: documented Pharmaceutical Ketamine and Esketamine procedure.
• CNESST Quebec: no formal listing; LATMP s.189 case-by-case pathway.

Quebec Bill 59 and the PTSD presumption for workers

Before Bill 59, Quebec workers with psychological injuries faced a significant barrier: they had to prove, on the balance of probabilities, that their PTSD was caused by their employment. For many first responders and other workers regularly exposed to traumatic events, that burden was difficult to meet even when the causal link seemed obvious.

Loi modernisant le régime de santé et de sécurité du travail (Bill 59, assented October 6, 2021, provisions in force 2022–2024) changed that framework. Bill 59 added post-traumatic stress disorder (syndrome de stress post-traumatique) to the list of occupational diseases under LATMP. Workers who have been repeatedly or extremely exposed to serious injury, sexual violence, threat of death, or actual death (not from natural causes) in the course of their employment are presumed to have an occupational disease when diagnosed with PTSD [Assemblée nationale du Québec 2021].

Critically, the presumption applies to first responders — provincial police (Sûreté du Québec), municipal police, paramedics, firefighters, corrections officers, and related occupations — even when exposure to traumatic situations is a normal feature of their work. Prior to Bill 59, CNESST could deny claims on the basis that traumatic exposure was an inherent occupational risk. The presumption closes that gap.

Pro tip: The Bill 59 PTSD presumption accelerates the underlying claim — it shifts the burden of proof to CNESST if they wish to deny on work-relatedness grounds. It does NOT automatically approve specific treatments. Treatment reimbursement (including ketamine or psychedelic therapy) still requires a separate, documented request under LATMP section 189.

Which Quebec workers benefit most from the Bill 59 presumption

Workers most likely to benefit from the PTSD presumption for compensation purposes:

• Sûreté du Québec and municipal police officers
• Firefighters (municipal, industrial, and wildland)
• Paramedics and other emergency medical workers
• Corrections officers
• Healthcare workers with documented traumatic workplace exposures
• Industrial workers with a documented acute traumatic event (explosion, serious injury to a colleague, etc.)

Workers outside these categories with compensable PTSD still file with CNESST — they simply do not benefit from the presumption and must document the work-related causation through physician and psychiatric evidence.

Does CNESST cover ketamine therapy for PTSD or chronic pain?

CNESST has not published a formal position on ketamine therapy for PTSD or chronic pain. Under the LATMP section 189 framework, reimbursement is possible on a case-by-case basis when the prescribing physician establishes the three conditions described above. Evidence from peer-reviewed research supports the clinical justification a physician would need to provide.

What the evidence shows for ketamine and PTSD

The randomized controlled trial evidence base for ketamine in PTSD has strengthened considerably since 2021:

Feder et al. (2021), in the first RCT of repeated ketamine infusions for chronic PTSD (n=30), found that 67% of participants in the ketamine group were treatment responders at two weeks, compared with 20% in the midazolam (active placebo) group. The between-group difference on the Clinician-Administered PTSD Scale (CAPS-5) was 11.88 points (SE=3.96; d=1.13), a large effect size [Feder et al. 2021, American Journal of Psychiatry].

Murrough et al. (2014) demonstrated in a proof-of-concept RCT (n=41) that a single IV ketamine infusion produced significant, rapid PTSD symptom reduction 24 hours post-infusion compared with midazolam, with a mean difference of 12.7 points on the Impact of Event Scale-Revised [Murrough et al. 2014, JAMA Psychiatry].

A 2024 meta-analysis and systematic review covering veteran populations found ketamine effective across chronic pain, depression, and PTSD, with particular relevance for first responders and injured workers who commonly present with comorbid conditions [Frontiers in Psychiatry 2024].

What the evidence shows for ketamine and chronic pain

For compensable chronic pain conditions (complex regional pain syndrome, refractory neuropathic pain, musculoskeletal chronic pain), a 2023 meta-analysis of 16 studies (n=1,080 patients) found IV ketamine produced a statistically significant reduction in pain scores (mean difference -1.05; 95% CI -1.72 to -0.39; p=0.002) [Odutola et al. 2023, Medicine Advances].

The Canadian community program at Edmonton (Alberta), in operation since 2015, has demonstrated practical implementation of step-down IV-to-intranasal/sublingual ketamine for treatment-resistant depression and comorbid conditions in a public hospital setting — the model most analogous to what Quebec-based CNESST-covered workers might access [Swainson et al. 2023, Frontiers in Psychiatry].

Key stat: In Feder et al. (2021), 67% of the ketamine group were treatment responders at two weeks, versus 20% of the active placebo group — a difference that represents a large effect size (d=1.13) in a population with chronic, treatment-resistant PTSD.

Off-label framing for ketamine in Quebec

In Quebec, ketamine is approved by Health Canada as an anaesthetic. Its use for PTSD, depression, anxiety, and chronic pain is off-label. Quebec physicians prescribing ketamine off-label for psychiatric or pain indications do so under CMQ (Collège des médecins du Québec) physician obligations, which require documented medical justification for off-label prescribing. No separate CMQ ketamine-specific guidance document has been published as of May 2026; physicians follow CMQ general standards for off-label practice.

Does CNESST cover psilocybin or MDMA therapy?

Neither psilocybin nor MDMA-assisted therapy is formally listed on any Canadian workers' compensation formulary, including CNESST. Both require Health Canada Special Access Program (SAP) authorization before any treatment can occur.

Psilocybin SAP: Health Canada's SAP is primarily approved for adults with treatment-resistant major depressive disorder (TRD) or distress associated with a life-threatening illness. SAP approval is case-by-case and is not guaranteed. PsyCan reported in September 2025 that approval rates declined sharply — approximately half the rate of the prior year [PsyCan 2025].

MDMA SAP: Health Canada's SAP for MDMA is primarily approved for adults with PTSD. The confirmatory Phase 3 trial (MAPP2, Mitchell et al. 2023) found that 71.2% of participants receiving MDMA-assisted therapy no longer met PTSD diagnostic criteria at 18 weeks, compared with 47.6% in the placebo group (p<0.001, n=104) [Mitchell et al. 2023, Nature Medicine]. The foundational MAPP1 trial (Mitchell et al. 2021) showed 67% of MDMA-group participants no longer met PTSD criteria vs 32% placebo (p<0.0001, n=90, d=0.91) [Mitchell et al. 2021, Nature Medicine].

Despite this strong evidence, a CNESST case-by-case reimbursement request for SAP-authorized psilocybin or MDMA therapy for a compensable PTSD claim is theoretically possible under LATMP section 189 — but no documented precedent for this exists as of 2026. The realistic pathway for CNESST-covered workers in 2026 remains ketamine/esketamine specifically.

CNESST and RAMQ — two separate Quebec payers

A frequent source of confusion for Quebec workers: CNESST and RAMQ are distinct institutions with different eligibility requirements and coverage scopes.

The Farzin/Stephan RAMQ precedent — in which Drs. Houman Farzin and Jean-François Stephan of the Jewish General Hospital (McGill University) successfully billed RAMQ for SAP-authorized psilocybin-assisted psychotherapy in June 2022 — applies specifically to RAMQ, not to CNESST. For the full RAMQ psilocybin pathway, see Quebec RAMQ public funding for psychedelic therapy.

The role of Quebec's Bill 21 and the OPQ psychothérapeute title

Any discussion of psychedelic-assisted or ketamine-assisted psychotherapy in Quebec requires understanding Bill 21 (Loi modifiant le Code des professions et d'autres dispositions législatives dans le domaine de la santé mentale et des relations humaines, 2009, c.28). Bill 21 reserves psychotherapy as a regulated act in Quebec.

The title psychothérapeute is restricted in Quebec to:

1. Physicians (members of CMQ)
2. Psychologists (members of OPQ — Ordre des psychologues du Québec)
3. Members of designated professional orders holding an OPQ psychotherapy permit (permis de psychothérapeute)

Eligible professions for the OPQ permit include social workers, nurses, occupational therapists, guidance counsellors, criminologists, psychoeducators, and conjugal and family therapists — each must meet four additional requirements: membership in their order, a master's degree in mental health and human relations, 765 hours of theoretical training across eight areas, and 600 hours of supervised practicum.

The practical implication for CNESST-covered workers: The psychotherapy component of ketamine-assisted psychotherapy or any SAP-authorized psychedelic-assisted psychotherapy must be delivered by Bill 21-eligible providers. A physician or OPQ-registered psychologist can deliver the full treatment. A therapist from another profession requires an OPQ permit.

Practical steps to pursue CNESST coverage for ketamine therapy

For a Quebec worker with an accepted CNESST claim seeking ketamine-assisted therapy reimbursement, the practical sequence is:

1. Confirm the accepted CNESST claim. The compensable condition (PTSD under Bill 59 presumption, or chronic pain, or other occupational disease) must be formally accepted by CNESST before any treatment reimbursement request can proceed.

2. Obtain a physician prescription linking ketamine to the compensable condition. A CMQ-registered physician (typically a psychiatrist or pain medicine specialist) must prescribe ketamine specifically for the accepted compensable injury. The prescription must establish clinical rationale.

3. Document conventional treatment failures. CNESST and TAT jurisprudence on medical cannabis and non-standard treatments consistently requires evidence that standard therapies were explored before alternative medications. For PTSD, this typically means trials of first-line pharmacotherapy (SSRIs, SNRIs) and evidence-based psychotherapy. For chronic pain, it means documentation of analgesics, physiotherapy, and related modalities.

4. Submit a formal reimbursement request under LATMP section 189 through the prescribing physician and CNESST case manager. Include the clinical rationale, treatment plan, and conventional treatment documentation.

5. If CNESST denies the request: Contest the decision at the Tribunal administratif du travail (TAT). Since April 2023 (LATMP amendments under Bill 59), certain CNESST decisions can be contested directly at TAT within 60 days; others require a CNESST review request within 30 days first. TAT — contesting a CNESST decision. Specialized workers' compensation lawyers and the Bureau des services juridiques can assist.

Watch out: CNESST case managers may be unfamiliar with ketamine-assisted therapy. A well-documented physician letter citing peer-reviewed evidence (such as Feder et al. 2021 and Odutola et al. 2023) and establishing the link to the compensable condition is essential. Do not assume the case manager has reviewed the current evidence base.

How ATMA CENA supports Quebec workers with compensable PTSD or chronic pain

ATMA CENA's clinical team supports Quebec workers through the preparation and integration phases of psychedelic-assisted or ketamine-assisted therapy. ATMA CENA does not initiate CNESST claims or submit reimbursement requests — that process belongs to the treating physician and the CNESST case file. ATMA CENA's role is in the clinical framework surrounding treatment:

• Preparation and integration support through the three-phase psychedelic-assisted therapy model (preparation, dosing, integration)
• Find care near you: ATMA CENA can work alongside a worker's existing CNESST-affiliated physician or Quebec mental health therapist (where Bill 21-eligible) so that the established care relationship continues while ATMA CENA's clinical infrastructure supports the psychedelic or ketamine-specific components

Frequently asked questions

Does CNESST cover ketamine therapy for PTSD?

CNESST has no formal formulary listing for ketamine. However, under section 189 of LATMP, CNESST can reimburse medications prescribed to treat a compensable occupational injury on a case-by-case basis. Two randomized controlled trials support ketamine's efficacy for PTSD [Feder et al. 2021; Murrough et al. 2014]. A Quebec physician must prescribe ketamine, document conventional treatment failures, and link the prescription to the accepted CNESST claim. If CNESST denies, workers can appeal at the Tribunal administratif du travail (TAT) within 30–60 days.

Does CNESST cover psilocybin or MDMA therapy?

No CNESST precedent exists for psilocybin or MDMA-assisted therapy as of 2026. Both substances require Health Canada SAP authorization before treatment can occur. SAP approvals declined sharply in 2025 [PsyCan 2025]. A case-by-case CNESST claim under LATMP s.189 is theoretically possible after SAP authorization but is uncommon. The realistic 2026 CNESST pathway for compensable PTSD remains ketamine specifically.

What is Quebec's Bill 59 PTSD presumption?

Bill 59 (assented October 2021, in force 2022–2024) added PTSD to Quebec's occupational disease list under LATMP. Workers repeatedly or extremely exposed to traumatic events (serious injury, sexual violence, threat of death, or actual death) in their employment are presumed to have an occupational disease when diagnosed with PTSD. First responders (police, firefighters, paramedics, corrections officers) benefit from this presumption even when traumatic exposure is a normal feature of their work.

Does the Bill 59 PTSD presumption automatically approve treatment?

No. The presumption accelerates claim acceptance by shifting the burden of proof on causation to CNESST. It does not automatically approve specific treatments. Treatment reimbursement (including ketamine therapy) still requires a separate documented request under LATMP section 189.

What is the difference between CNESST and RAMQ for psychedelic therapy?

CNESST is Quebec's workers' compensation body — it covers treatments for compensable occupational injuries only, case-by-case. RAMQ is Quebec's public health insurance — it established a psilocybin-funding precedent in December 2022 (the Farzin/Stephan billing precedent) for SAP-approved patients. These are separate payers with different eligibility. Workers with compensable conditions may pursue CNESST; all Quebec residents with RAMQ coverage may pursue the RAMQ psilocybin pathway. See Quebec RAMQ public funding for psychedelic therapy.

What is the appeal process if CNESST denies my treatment request?

CNESST decisions can be contested at the Tribunal administratif du travail (TAT). Since April 2023, certain CNESST decisions can be contested directly at TAT within 60 days of notification; others require a CNESST review request within 30 days first. Specialized workers' compensation lawyers assist with complex appeals.

Can I use the RAMQ psilocybin precedent to support a CNESST claim?

The Farzin/Stephan RAMQ precedent established that RAMQ modified billing codes for psilocybin-assisted psychotherapy as a medically insured service under RAMQ — it does not directly bind CNESST decisions under LATMP. However, the precedent demonstrates that Quebec's health system has formally recognized psilocybin-assisted psychotherapy as a legitimate medical service, which may be cited as contextual evidence in a CNESST or TAT proceeding.

Who can deliver the psychotherapy component of ketamine-assisted therapy in Quebec?

Under Bill 21 (2009), psychotherapy is a reserved act in Quebec. The therapist delivering the psychotherapy component must be a physician (CMQ), a psychologist (OPQ member), or a designated professional holding an OPQ permis de psychothérapeute. The title psychothérapeute is restricted; only OPQ permit-holders, physicians, and psychologists may use it.

Is ATMA CENA's Montreal clinic able to support CNESST claims?

What conventional treatments should I try before requesting CNESST ketamine coverage?

CNESST and TAT jurisprudence on non-standard medications requires documentation of conventional treatment attempts. For PTSD, conventional first-line treatments include pharmacotherapy (SSRIs, SNRIs such as sertraline or venlafaxine) and evidence-based psychotherapy (prolonged exposure therapy, cognitive processing therapy, EMDR). For chronic pain, prior treatments typically include analgesics, physiotherapy, and specialist consultation. Document failures or intolerances carefully with your physician before submitting a ketamine reimbursement request.

Important compliance information

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada's Special Access Program (SAP). SAP approval is granted on a case-by-case basis and is not guaranteed. Approval rates declined sharply in 2025 [PsyCan 2025]. Psilocybin SAP is primarily approved for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA SAP is primarily approved for adults with PTSD. Neither psilocybin nor MDMA is formally listed on any Canadian workers' compensation formulary, including CNESST, at this time [Health Canada SAP Notice].

In Quebec, ketamine is approved by Health Canada as an anaesthetic. Its use for PTSD, depression, anxiety, and chronic pain is off-label, regulated under CMQ (Collège des médecins du Québec) physician obligations. Off-label prescribing requires documented medical justification by the prescribing physician.

CNESST coverage described in this article is case-by-case under LATMP section 189. CNESST does not maintain a drug formulary for ketamine, psilocybin, or MDMA. This article does not constitute legal or medical advice. Injured workers should consult a CMQ-registered physician and, where appropriate, a specialized workers' compensation lawyer for advice specific to their claim.

Sources

1. Feder, A. et al. (2021). "A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder." American Journal of Psychiatry, 178(2), 193–202. https://psychiatryonline.org/doi/10.1176/appi.ajp.2020.20050596
2. Murrough, J.W. et al. (2014). "Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder: A Randomized Clinical Trial." JAMA Psychiatry, 71(6), 681–688. https://pubmed.ncbi.nlm.nih.gov/24740528/
3. Mitchell, J.M. et al. (2021). "MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study." Nature Medicine, 27(6), 1025–1033. https://www.nature.com/articles/s41591-021-01336-3
4. Mitchell, J.M. et al. (2023). "MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial." Nature Medicine, 29(10), 2473–2480. https://www.nature.com/articles/s41591-023-02565-4
5. Goodwin, G.M. et al. (2022). "Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression." New England Journal of Medicine, 387, 1637–1648. https://www.nejm.org/doi/full/10.1056/NEJMoa2206443
6. Swainson, J. et al. (2023). "Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada." Frontiers in Psychiatry, 14:1283733. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full
7. Odutola, O. et al. (2023). "IV ketamine infusion therapy for chronic pain: A systematic review and meta-analysis." Medicine Advances. https://onlinelibrary.wiley.com/doi/full/10.1002/med4.45
8. Frontiers in Psychiatry (2024). Ketamine meta-analysis for chronic pain, depression, and PTSD in veterans. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1338581/full
9. McGowan, N.M. et al. (2025). "Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial." Journal of Psychopharmacology. https://journals.sagepub.com/doi/10.1177/02698811251362390
10. Assemblée nationale du Québec (2021). Projet de loi n° 59 — Loi modernisant le régime de santé et de sécurité du travail. https://www.assnat.qc.ca/fr/travaux-parlementaires/projets-loi/projet-loi-59-42-1.html
11. CNESST — Compensation and reimbursements. https://www.cnesst.gouv.qc.ca/en/procedures-and-forms/workers/compensation-and-reimbursements
12. Tribunal administratif du travail (TAT) — Contesting a CNESST decision. https://www.tat.gouv.qc.ca/sante-et-securite-du-travail/contestation-dune-decision-de-la-cnesst
13. Health Canada (2022). Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
14. PsyCan (2025). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
15. TheraPsil (2022). Quebec first province to cover costs of psilocybin-assisted psychotherapy, done by two physicians. https://therapsil.ca/quebec-first-province-to-cover-costs-of-psilocybin-assisted-psychotherapy-done-by-two-physicians/
16. OPQ (Ordre des psychologues du Québec) — Psychotherapist permit requirements. https://www.ordrepsy.qc.ca/resume-quatre-exigences-psychotherapeute

Related articles

• Workers' Compensation for Psychedelic-Assisted Therapy in Canada — cross-province comparison
• Insurance Coverage for Psychedelic-Assisted Therapy in Canada — private and group insurance coverage overview
• Quebec RAMQ Public Funding for Psychedelic Therapy — RAMQ psilocybin pathway (distinct from CNESST)
• Psilocybin Therapy in Quebec Under the SAP — psilocybin SAP pathway in Quebec
• MDMA-Assisted Therapy in Quebec — MDMA SAP pathway in Quebec
• Ketamine-Assisted Therapy in Montreal — Montreal ketamine therapy access
• How to Access Psilocybin Therapy in Canada — SAP pathway detail

Last updated: 2026-05-06. This article is reviewed every 3 months given the rapidly evolving regulatory landscape for psychedelic-assisted therapy in Canada.